Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Rituximab (Test Product, Zydus) vs Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL)

Rituximab is frequently used to treat a variety of B-cell lymphoma. Rituximab alone can produce significant response rates and long-term remissions in several B cell malignancies, whereas combining rituximab with chemotherapy improves overall survival in others. Rituximab is an important part of the treatment for anti-B cell malignancies, although it does not work for everyone, and resistance to it is prevalent. In order to further develop rituximab, which is already a highly effective treatment, it is critical to understand the pathways by which it elicits anti-tumor responses. Diffuse large B-cell lymphoma (DLBCL) is a kind of lymphoma that affects B cells, which are responsible for antibody production.